Drug Profile
Sodium sulfide
Alternative Names: IK-1001; Metabolic modulation therapeutics - Ikaria HoldingsLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Fred Hutchinson Cancer Research Center
- Developer Ikaria Holdings
- Class Anti-ischaemics; Sulfides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Ischaemic heart disorders; Reperfusion injury
Most Recent Events
- 01 May 2015 Ikaria terminates a phase I trial in patients with renal impairment in USA (NCT00879645)
- 01 Oct 2010 Discontinued - Phase-II for Ischaemic heart disorders in Australia (IV)
- 01 Oct 2010 Discontinued - Phase-II for Ischaemic heart disorders in Canada (IV)